Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives
                                
                                    
                                        作者:Jürg Zimmermann、Elisabeth Buchdunger、Helmut Mett、Thomas Meyer、Nicholas B. Lydon                                    
                                    
                                        DOI:10.1016/s0960-894x(96)00601-4
                                    
                                    
                                        日期:1997.1
                                    
                                    Due to its relatively clear etiology, Chronic myelogenous leukemia (CML) represents an ideal disease target for a therapy using a selective inhibitor of the Bcr-Abl tyrosine protein kinase. Extensive optimization of the class of phenylamino-pyrimidines yielded highly potent and selective Bcr-Abl kinase inhibitors. Compound 1 shows high potency (IC50 = 38 nM) and selectivity for the Abl tyrosine protein kinase at the in vitro level. (C) 1997, Elsevier Science Ltd.